NASDAQ:MDGL Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis $284.49 +1.03 (+0.36%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$276.63▼$289.9150-Day Range$220.06▼$292.9652-Week Range$119.76▼$299.98Volume167,769 shsAverage Volume488,499 shsMarket Capitalization$6.06 billionP/E RatioN/ADividend YieldN/APrice Target$348.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Madrigal Pharmaceuticals alerts: Email Address Madrigal Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.69 Rating ScoreUpside/Downside22.5% Upside$348.50 Price TargetShort InterestBearish19.29% of Shares Sold ShortDividend StrengthN/ASustainability-0.92Upright™ Environmental ScoreNews Sentiment0.45Based on 7 Articles This WeekInsider TradingSelling Shares$6.13 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($27.70) to ($17.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.24 out of 5 starsMedical Sector162nd out of 936 stocksPharmaceutical Preparations Industry67th out of 436 stocks 3.3 Analyst's Opinion Consensus RatingMadrigal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 10 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageMadrigal Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Madrigal Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted19.29% of the outstanding shares of Madrigal Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMadrigal Pharmaceuticals has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Madrigal Pharmaceuticals has recently increased by 0.74%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMadrigal Pharmaceuticals does not currently pay a dividend.Dividend GrowthMadrigal Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMadrigal Pharmaceuticals has received a 73.28% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Madrigal Pharmaceuticals is -0.92. Previous Next 2.5 News and Social Media Coverage News SentimentMadrigal Pharmaceuticals has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Madrigal Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 4 people have searched for MDGL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows9 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Madrigal Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,129,127.00 in company stock.Percentage Held by Insiders23.92% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.50% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Madrigal Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($27.70) to ($17.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Madrigal Pharmaceuticals is -12.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Madrigal Pharmaceuticals is -12.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMadrigal Pharmaceuticals has a P/B Ratio of 13.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Madrigal Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Madrigal Pharmaceuticals Stock (NASDAQ:MDGL)Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.Read More MDGL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDGL Stock News HeadlinesJuly 25 at 4:38 AM | americanbankingnews.comCantor Fitzgerald Reiterates Neutral Rating for Madrigal Pharmaceuticals (NASDAQ:MDGL)July 24 at 8:00 AM | globenewswire.comMadrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024July 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 23 at 2:57 PM | investorplace.com7 Biotech Stocks to Keep on Your Clinical RadarJuly 19, 2024 | americanbankingnews.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $348.17 Average PT from BrokeragesJuly 19, 2024 | americanbankingnews.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded to "Sell" at StockNews.comJuly 18, 2024 | americanbankingnews.comJMP Securities Raises Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target to $385.00June 30, 2024 | fool.comIs Madrigal Pharmaceuticals a Millionaire Maker?July 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 28, 2024 | fool.comIs Madrigal Pharmaceuticals Stock a Buy?June 16, 2024 | fool.comThinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.June 15, 2024 | fool.comWhere Will Madrigal Pharmaceuticals Be in 3 Years?June 12, 2024 | seekingalpha.comMadrigal Pharmaceuticals: The GLP-1 Threat May Be OvercookedJune 10, 2024 | fool.comBetter Biotech Stock: Viking Therapeutics vs. Madrigal PharmaceuticalsJune 9, 2024 | seekingalpha.comMadrigal May Not Be Able To Shrug GLP-1 Drugs For LongJune 6, 2024 | globenewswire.comMadrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL CongressMay 29, 2024 | finance.yahoo.comMadrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL CongressMay 24, 2024 | finance.yahoo.comInsider Sale at Madrigal Pharmaceuticals Inc (MDGL): Senior VP, Chief Pharmaceutical ...See More Headlines Receive MDGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Confirmed)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:MDGL CUSIP87162T20 CIK1157601 Webwww.madrigalpharma.com Phone(267) 824-2827Fax781-274-8228Employees376Year Founded2011Price Target and Rating Average Stock Price Target$348.50 High Stock Price Target$410.00 Low Stock Price Target$150.00 Potential Upside/Downside+22.7%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($23.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-373,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-128.60% Return on Assets-78.52% Debt Debt-to-Equity Ratio0.14 Current Ratio9.39 Quick Ratio9.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$20.53 per share Price / Book13.83Miscellaneous Outstanding Shares21,310,000Free Float16,214,000Market Cap$6.05 billion OptionableOptionable Beta-0.42 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Rebecca A. Taub M.D. (Age 72)Founder, Chief Medical Officer, President of Research & Development and Director Comp: $939.83kMr. Brian J. Lynch J.D. (Age 62)Senior VP & General Counsel Comp: $763.75kMr. Alex G. Howarth (Age 55)Executive Officer Comp: $757.26kMr. William J. Sibold (Age 58)CEO, President & Director Ms. Mardi C. Dier (Age 60)CFO, Principal Financial Officer, Principal Accounting Officer & Senior VP Mr. Ronald FilippoChief Information OfficerMs. Tina E. VenturaChief Investor Relations OfficerDr. Kianoush Motesharei Ph.d. (Age 54)Senior Vice President of Business & Corporate Development Mr. Clint WallaceChief Human Resources OfficerMr. Edward ChiangSenior Vice President of Clinical & Technical OperationsMore ExecutivesKey CompetitorsDicerna PharmaceuticalsNASDAQ:DRNARocket PharmaceuticalsNASDAQ:RCKTIntercept PharmaceuticalsNASDAQ:ICPTY-mAbs TherapeuticsNASDAQ:YMABGeneration BioNASDAQ:GBIOView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 15,932 shares on 7/26/2024Ownership: 0.346%AMI Asset Management CorpSold 4,133 shares on 7/25/2024Ownership: 0.026%Calamos Advisors LLCBought 499 shares on 7/25/2024Ownership: 0.019%China Universal Asset Management Co. Ltd.Sold 1,297 shares on 7/20/2024Ownership: 0.012%First Horizon Advisors Inc.Bought 98 shares on 7/20/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions MDGL Stock Analysis - Frequently Asked Questions How have MDGL shares performed this year? Madrigal Pharmaceuticals' stock was trading at $231.38 on January 1st, 2024. Since then, MDGL stock has increased by 23.0% and is now trading at $284.49. View the best growth stocks for 2024 here. How were Madrigal Pharmaceuticals' earnings last quarter? Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) posted its quarterly earnings data on Tuesday, May, 7th. The biopharmaceutical company reported ($7.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($6.06) by $1.32. Who are Madrigal Pharmaceuticals' major shareholders? Madrigal Pharmaceuticals' top institutional shareholders include Bank of New York Mellon Corp (0.35%), Hennion & Walsh Asset Management Inc. (0.10%), Raymond James & Associates (0.10%) and Assenagon Asset Management S.A. (0.03%). Insiders that own company stock include Bros Advisors Lp Baker, Rebecca Taub, Fred B Craves, Paul A Friedman, Brian Joseph Lynch, Richard S Levy, Robert E Waltermire and Remy Sukhija. View institutional ownership trends. How do I buy shares of Madrigal Pharmaceuticals? Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Madrigal Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Ayala Pharmaceuticals (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN) and CRISPR Therapeutics (CRSP). This page (NASDAQ:MDGL) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
